• China Center of Drug Evaluation granted Priority Review designation for Bayer’s FXIa inhibitor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.